Can Moderna Meet Its COVID Vaccine Expectations?
Non-Profit Competition Will Hit Revenues
Analysts have cut forecasts for Moderna’s COVID-19 vaccine – but there is still much to play for as key readouts approach.
You may also be interested in...
The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector.
Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.